Cytokinetics (CYTK) Mentioned Positively at Morgan Stanley

Morgan Stanley analyst Jeffrey Hung reiterated an Overweight rating and $60.00 price target on Cytokinetics (NASDAQ: CYTK).

The analyst comments "Topline Phase 3 SEQUOIA-HCM results for Cytokinetics' drug aficamten are expected in late December. We believe the study is likely to read out positively, but how much data will be released is unclear as some aspects could be embargoed until a potential presentation at the ACC meeting in April."

For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.

Shares of Cytokinetics closed at $32.31 yesterday.

You May Also Be Interested In

• Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
• Medtronic, Inc. (MDT) PT Lowered to $101 at Needham
• Bernstein SocGen Group Starts Cipher Mining (CIFR) at Outperform